We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
-11.22%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$960M
AUM Growth
-$305M
Cap. Flow
-$75.3M
Cap. Flow %
-7.85%
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$70.9M
2
IRON icon
Disc Medicine
IRON
+$16.5M
3
EYPT icon
EyePoint Inc
EYPT
+$12.9M
4
SVRA icon
Savara
SVRA
+$10.5M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.06M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$61.2M
2
GERN icon
Geron
GERN
+$57.4M
3
GPCR icon
Structure Therapeutics
GPCR
+$37.1M
4
ATXS
Astria Therapeutics
ATXS
+$24.6M
5
KALV
KalVista Pharmaceuticals
KALV
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.59B
$116M 12.08%
3,670,206
+100,000
+3% +$3.47M
DYN icon
2
Dyne Therapeutics
DYN
$4.68B
$93.5M 9.75%
2,650,150
– –
ABVX
3
Abivax
ABVX
$9.89B
$80.1M 8.34%
6,056,596
+4,956,596
+451% +$70.9M
SLN
4
Silence Therapeutics
SLN
$834M
$62.6M 6.53%
3,295,350
– –
COGT icon
5
Cogent Biosciences
COGT
$6.02B
$58.7M 6.12%
6,964,375
+750,000
+12% +$5.69M
SVRA icon
6
Savara
SVRA
$1.08B
$49.8M 5.19%
12,362,205
+2,362,205
+24% +$10.5M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.3B
$41.8M 4.36%
149,283
– –
EWTX icon
8
Edgewise Therapeutics
EWTX
$4.64B
$40.9M 4.27%
2,272,728
– –
KROS icon
9
Keros Therapeutics
KROS
$219M
$40.2M 4.19%
879,344
– –
MLYS icon
10
Mineralys Therapeutics
MLYS
$2.26B
$37.3M 3.88%
3,185,185
– –
OCUL icon
11
Ocular Therapeutix
OCUL
$2.28B
$36.4M 3.79%
5,319,148
– –
TYRA icon
12
Tyra Biosciences
TYRA
$1.49B
$31.8M 3.31%
1,989,103
– –
KURA icon
13
Kura Oncology
KURA
$1.13B
$29.3M 3.06%
1,423,642
– –
GPCR icon
14
Structure Therapeutics
GPCR
$3.38B
$27.3M 2.84%
694,547
-903,874
-57% -$37.1M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$26.1M 2.72%
2,890,816
+850,000
+42% +$8.06M
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$25.1M 2.62%
2,761,861
-2,517,067
-48% -$24.6M
CMPS
17
Compass Pathways
CMPS
$1.9B
$23.3M 2.43%
3,858,000
– –
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
$22.4M 2.34%
550,000
– –
IRON icon
19
Disc Medicine
IRON
$3.07B
$21.9M 2.29%
+486,957
New +$16.5M
TRML
20
DELISTED
Tourmaline Bio
TRML
$19M 1.98%
1,477,593
– –
TARS icon
21
Tarsus Pharmaceuticals
TARS
$3.15B
$15.1M 1.58%
556,317
-237,512
-30% -$7.99M
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
$13.8M 1.44%
2,008,340
– –
VTGN icon
23
VistaGen Therapeutics
VTGN
$11.2M
$9.31M 0.97%
2,676,580
– –
TRDA icon
24
Entrada Therapeutics
TRDA
$273M
$8.34M 0.87%
584,955
– –
EYPT icon
25
EyePoint Inc
EYPT
$386M
$8.02M 0.84%
+922,335
New +$12.9M
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q2 2024 Portfolio in Review

As of Q2 2024, TCG Crossover Management held 35 positions worth $960M, down 24% from $1.26B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

TCG Crossover Management withdrew a net $75.3M in Q2 2024, closing 3 positions and reducing 4 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $61.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, TCG Crossover Management opened a new position in Disc Medicine worth $21.9M.

  • TCG Crossover Management's largest Q2 2024 buy was Disc Medicine: 486,957 shares worth $21.9M.
  • TCG Crossover Management added most to Abivax in Q2 2024, an estimated $70.9M increase.
  • TCG Crossover Management's biggest Q2 2024 reduction was Structure Therapeutics, cutting an estimated $37.1M.
  • TCG Crossover Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $61.2M.
  • TCG Crossover Management's ten largest holdings make up 65% of its $960M portfolio in Q2 2024.
  • TCG Crossover Management opened 2 new positions and closed 3 in Q2 2024.
  • TCG Crossover Management's portfolio value fell 24% quarter-over-quarter to $960M.

Based on TCG Crossover Management's 13F filing for Q2 2024, filed 14 Aug 2024.